Arcus Biosciences logo
Arcus Biosciences RCUS
$ 15.62 -1.64%
report update icon

Quarterly report 2026-Q3
added 11-04-2026

Arcus Biosciences Accounts Payables | RCUS

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.
Main types of accounts payable
Type of liabilityExample
To suppliers and contractorsGoods received but not yet paid for
Taxes and feesVAT, income tax, etc., not paid on time
SalariesEmployee wages not paid
To budgetsInsurance contributions to funds not paid
To foundersFounders provided borrowed funds
To banksOverdue loan payments
OtherFines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance
  1. Liquidity and solvency
    Accounts payable are part of short-term liabilities, so they affect liquidity ratios
  2. Financial stability
    The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
  3. Capital turnover
    Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
  4. Risks and reputation
    Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Arcus Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
42 M 18 M 17 M 20 M 10 M 15.7 M 4.7 M 3.1 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
42 M 3.1 M 16.3 M

Quarterly Accounts Payables Arcus Biosciences

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
44 M 34 M 39 M 42 M 42 M 29 M 22 M 18 M 13 M 15 M 16 M 17 M 17 M 12 M 28 M 20 M 10.5 M 22 M 18.1 M 10 M 13.2 M 17 M 24.5 M 15.7 M 8.1 M 12.1 M 2.43 M 4.7 M 2.9 M 2.45 M 2.83 M 3.1 M 2.11 M 5.39 M 3.92 M 3.82 M 3.82 M 3.82 M 3.82 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
44 M 2.11 M 15.5 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer Accounts Payables Price % 24h Market Cap Country
Lyra Therapeutics Lyra Therapeutics
LYRA
663 K - - $ 24.9 M usaUSA
Brickell Biotech Brickell Biotech
BBI
406 K - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
4.43 M - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
2.4 M - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
1.41 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
1.45 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
4.16 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
1.28 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
14.9 M $ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
702 K - 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
2.91 M - -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
189 K - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
155 K - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
2 M $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
1.95 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
1.98 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
890 K - - $ 35.3 M usaUSA
Axcella Health Axcella Health
AXLA
4.71 M - -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
368 K - - $ 24.2 M usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
12.2 M - -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
1.23 M - -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
5.2 M - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
9.03 M - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
11.3 M - - $ 69.7 B britainBritain
Atreca Atreca
BCEL
1.74 M - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
614 K - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
315 K - - $ 109 M usaUSA
Akouos Akouos
AKUS
1.28 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
45.4 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
1.76 M - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
3.61 M - - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
251 K - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
1.09 M - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
2.12 M - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
3.47 M - - $ 23.9 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
8.11 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
6.52 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
34.3 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
1.38 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
3.29 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
13.7 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
936 K - - $ 728 M usaUSA